TVARDI THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TVARDI THERAPEUTICS, INC. (TVRD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.25 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $1.25M, a 24.88% decline year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $1.34M, a 57.81% decline year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $1.51M, a 51.64% decline year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $1.66M, a 44.15% decline year-over-year.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.71M, a 47.21% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $12.71M, a 11.40% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.35M, a 19.64% decline from fiscal 2021.
- TVARDI THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $17.85M, a 42.96% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.25M 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $6.71M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $1.34M 10-Q · filed 2024-11-14 | $2.85M derived: sum of 2 quarters · filed 2024-11-14 | $4.50M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2024-06-30 | $1.51M 10-Q · filed 2024-11-14 | $3.17M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2024-03-31 | $1.66M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $12.71M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $3.17M 10-Q · filed 2024-11-14 | $6.29M derived: sum of 2 quarters · filed 2024-11-14 | $9.26M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $3.12M 10-Q · filed 2024-11-14 | $6.09M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $2.97M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $14.35M 10-K · filed 2025-03-11 | |||
| 2022-09-30 | $3.52M 10-Q · filed 2023-11-13 | $7.75M derived: sum of 2 quarters · filed 2023-11-13 | $12.02M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $4.23M 10-Q · filed 2023-11-13 | $8.50M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $4.27M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $17.85M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | $3.49M 10-Q · filed 2022-11-07 | $6.86M derived: sum of 2 quarters · filed 2022-11-07 | $9.61M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $3.38M 10-Q · filed 2022-11-07 | $6.12M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $2.74M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $12.49M 10-K · filed 2023-03-06 | |||
| 2020-09-30 | $3.31M 10-Q · filed 2021-11-08 | $6.30M derived: sum of 2 quarters · filed 2021-11-08 | $9.14M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $2.99M 10-Q · filed 2021-11-08 | $5.84M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $2.85M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $10.59M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.83M 10-Q · filed 2020-11-09 | $5.52M derived: sum of 2 quarters · filed 2020-11-09 | $7.75M derived: sum of 3 quarters · filed 2020-11-09 | $9.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.68M 10-Q · filed 2020-11-09 | $4.92M derived: sum of 2 quarters · filed 2020-11-09 | $6.94M derived: sum of 3 quarters · filed 2021-02-25 | $8.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.23M 10-Q · filed 2020-11-09 | $4.26M derived: sum of 2 quarters · filed 2021-02-25 | $6.08M derived: sum of 3 quarters · filed 2021-02-25 | $8.15M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.85M derived: sum of 2 quarters · filed 2021-02-25 | $5.91M derived: sum of 3 quarters · filed 2021-02-25 | $7.79M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.82M 10-Q · filed 2019-11-05 | $3.89M derived: sum of 2 quarters · filed 2019-11-05 | $5.76M 10-Q · filed 2018-11-06 | $7.51M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.07M 10-Q · filed 2019-11-05 | $3.94M 10-Q · filed 2018-08-07 | $5.69M derived: sum of 3 quarters · filed 2020-02-27 | $7.31M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.87M 10-Q · filed 2019-11-05 | $3.62M derived: sum of 2 quarters · filed 2020-02-27 | $5.24M derived: sum of 3 quarters · filed 2020-02-27 | $6.56M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $3.37M derived: sum of 2 quarters · filed 2020-02-27 | $4.68M derived: sum of 3 quarters · filed 2020-02-27 | $5.79M 10-K · filed 2020-02-27 |
| 2017-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.94M derived: sum of 2 quarters · filed 2018-11-06 | $4.05M 10-Q · filed 2018-11-06 | $4.88M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.43M 10-Q · filed 2018-08-07 | $3.25M derived: sum of 3 quarters · filed 2019-03-12 | $4.03M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $1.11M 10-Q · filed 2018-05-09 | $1.94M derived: sum of 2 quarters · filed 2019-03-12 | $2.71M derived: sum of 3 quarters · filed 2019-03-12 | $3.41M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.61M derived: sum of 2 quarters · filed 2019-03-12 | $2.30M derived: sum of 3 quarters · filed 2019-03-12 | $2.80M 10-K · filed 2019-03-12 |
| 2016-09-30 | $777.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.48M derived: sum of 2 quarters · filed 2017-11-02 | $1.97M 10-Q · filed 2017-11-02 | $2.68M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.19M 10-Q · filed 2017-08-03 | $1.90M derived: sum of 3 quarters · filed 2018-03-15 | $2.56M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $496.00K 10-Q · filed 2017-05-04 | $1.20M derived: sum of 2 quarters · filed 2018-03-15 | $1.86M derived: sum of 3 quarters · filed 2018-03-15 | $2.56M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $707.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.37M derived: sum of 2 quarters · filed 2018-03-15 | $2.07M derived: sum of 3 quarters · filed 2018-03-15 | $2.51M 10-K · filed 2018-03-15 |
| 2015-09-30 | $661.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.36M derived: sum of 2 quarters · filed 2016-11-04 | $1.81M 10-Q · filed 2016-11-04 | $2.15M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $701.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.15M 10-Q · filed 2016-08-04 | $1.49M derived: sum of 3 quarters · filed 2017-03-10 | $1.71M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $445.00K 10-Q · filed 2016-05-05 | $785.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.01M derived: sum of 3 quarters · filed 2017-03-10 | $1.46M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $562.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.02M derived: sum of 3 quarters · filed 2017-03-10 | $1.37M 10-K · filed 2017-03-10 |
| 2014-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $678.00K derived: sum of 2 quarters · filed 2015-11-09 | $1.03M 10-Q · filed 2015-11-09 | $1.04M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $809.00K 10-Q · filed 2015-08-10 | $822.00K derived: sum of 3 quarters · filed 2016-03-11 | $881.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $353.00K 10-Q · filed 2015-05-12 | $366.00K derived: sum of 2 quarters · filed 2016-03-11 | $425.00K derived: sum of 3 quarters · filed 2016-03-11 | |
| 2013-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $72.00K derived: sum of 2 quarters · filed 2016-03-11 | $123.00K 10-K · filed 2016-03-11 | |
| 2013-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $110.00K 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $51.00K 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $61.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |